What is AMPLY Discovery?
Founded in 2021, AMPLY Discovery operates at the intersection of computational biology and pharmacology. By leveraging advanced machine learning algorithms, the company systematically mines vast datasets to uncover alternative natural compounds with potent anti-infective properties. This AI-first approach allows for a more efficient identification of therapeutic candidates compared to traditional laboratory-based screening methods. Positioned within the burgeoning UK biotech ecosystem, AMPLY Discovery is effectively bridging the gap between digital data analytics and tangible medical breakthroughs, aiming to redefine the development cycle for novel therapeutics.
How much funding has AMPLY Discovery raised?
AMPLY Discovery has raised a total of $3.8M across 3 funding rounds:
Unspecified
$1M
Grant
$1M
Seed
$1.8M
Unspecified (2022): $1M with participation from Helix Way Partnership, QUBIS Innovation Fund, and Co-fund NI
Grant (2024): $1M led by UK Research & Innovation and Innosuisse
Seed (2025): $1.8M supported by Venture Science, British Business Bank, and Twin Path Ventures
Key Investors in AMPLY Discovery
Venture Science
Venture Science specializes in AI-driven quantitative investing, focusing on high-impact technology investments through data-informed strategies.
British Business Bank
The British Business Bank is a government-owned development bank dedicated to increasing the supply of credit to small and medium-sized enterprises.
Twin Path Ventures
Twin Path Ventures is an investment firm that specializes in backing AI-first startups from their inception, providing strategic guidance and ecosystem support.
What's next for AMPLY Discovery?
With the latest capital infusion, AMPLY Discovery is well-positioned to transition from its foundational research phase into more intensive clinical development and validation. The strategic focus will likely center on expanding its digital library of biological data and accelerating the lead optimization process for its primary drug candidates. As the company scales, it will need to navigate the complexities of regulatory approval while maintaining its competitive edge in AI-driven discovery. The involvement of specialized venture firms and government-backed innovation bodies suggests a clear path toward commercialization, with the potential to disrupt the anti-infective market through high-throughput, data-informed innovation.
See full AMPLY Discovery company page
